{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:35:59Z","timestamp":1767839759714,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T00:00:00Z","timestamp":1482364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.12.027","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T11:18:35Z","timestamp":1482578315000},"page":"596-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age"],"prefix":"10.1016","volume":"35","author":[{"given":"Line M.","family":"Lindgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille N.","family":"Tingskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette H.","family":"Justesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina S.","family":"Nedergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus J.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars V.","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Kromann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Thierry-Carstensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.027_b0005","unstructured":"World Health Organisation. Polio eradication & endgame strategic plan 2013-2018. WHO Press World Health Organisation, 20 Avenue Appia, Geneva, Switzerland 2013. Available from: URL: <http:\/\/www.polioeradication.org>."},{"issue":"210 Suppl 1","key":"10.1016\/j.vaccine.2016.12.027_b0010","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/infdis\/jiu128","article-title":"Affordable inactivated poliovirus vaccine: strategies and progress","volume":"1","author":"Okayasu","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.027_b0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coviro.2013.05.007","article-title":"Poliovirus vaccination options for achieving eradication and securing the endgame","volume":"3","author":"Estivariz","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"33 Suppl 1","key":"10.1016\/j.vaccine.2016.12.027_b0020","doi-asserted-by":"crossref","first-page":"A93","DOI":"10.1016\/j.vaccine.2014.12.076","article-title":"What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?","volume":"7","author":"Brenzel","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.027_b0025","unstructured":"Introduction of inactivated poliovirus vaccine and switch from trivalen to bivalent oral poliovirus vaccine - worldwide, 2013\u20132016. MMWR Recomm Rep 2016 March 7. Vol. 64 (25). p. 699\u2013702."},{"issue":"39","key":"10.1016\/j.vaccine.2016.12.027_b0030","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.vaccine.2008.07.026","article-title":"World wide experience with inactivated poliovirus vaccine","volume":"26","author":"Bonnet","year":"2008","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2016.12.027_b0035","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1016\/j.vaccine.2014.10.009","article-title":"The ethics of disease eradication","volume":"32","author":"Wilson","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.027_b0040","doi-asserted-by":"crossref","unstructured":"Polio vaccines: WHO position paper, January 2014\u2013recommendations. Vaccine, vol. 32(33); 2014. p. 4117\u20138 [July 16].","DOI":"10.1016\/j.vaccine.2014.04.023"},{"issue":"33","key":"10.1016\/j.vaccine.2016.12.027_b0045","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.vaccine.2015.02.011","article-title":"Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats","volume":"17","author":"Andreasen","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2016.12.027_b0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/erv.11.72","article-title":"A DTaP-IPV\/\/PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience","volume":"10","author":"Plotkin","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2016.12.027_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00431-005-1650-y","article-title":"Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age","volume":"164","author":"Vergara","year":"2005","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.vaccine.2016.12.027_b0060","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.vaccine.2003.09.011","article-title":"Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells","volume":"22","author":"Haastrup","year":"2004","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2016.12.027_b0065","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1016\/j.vaccine.2008.07.033","article-title":"Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age","volume":"26","author":"Pietrzyk","year":"2008","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2016.12.027_b0070","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.vaccine.2013.08.034","article-title":"Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience","volume":"28","author":"Thierry-Carstensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.027_b0075","series-title":"Enteroviruses. Diagnostic procedures for viral, rickettsial and chlamydial infections","author":"Melnick","year":"1976"},{"key":"10.1016\/j.vaccine.2016.12.027_b0080","doi-asserted-by":"crossref","unstructured":"Vidor E, Plotkin S. Poliovirus vaccine - inactivated. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed.; 2013. p. 573\u201397.","DOI":"10.1016\/B978-1-4557-0090-5.00034-3"},{"issue":"13","key":"10.1016\/j.vaccine.2016.12.027_b0085","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0264-410X(96)00092-8","article-title":"Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations\u2013III","volume":"14","author":"Aggerbeck","year":"1996","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2016.12.027_b0090","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1016\/j.vaccine.2015.06.036","article-title":"Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV","volume":"33","author":"Gajdos","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.027_b0095","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1128\/CVI.00682-14","volume":"22","author":"Embree","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2016.12.027_b0100","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00431-014-2318-2","article-title":"How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study","volume":"173","author":"Bergfors","year":"2014","journal-title":"Eur J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T11:53:14Z","timestamp":1536148394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16312348"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}